急性髓系白血病FLT3-ITD插入位点的分子特征与预后影响:RATIFY研究结果
在RATIFY试验的452例随机化AML患者中,采用二代测序鉴定出908个FLT3-ITD插入位点,分为JMDsole、JMD/TKD1和TKD1sole三组。三组4年OS概率分别为0.44、0.50和0.30(P=0.032),TKD1sole为不利预后因素,米哚妥林仅对JMDsole组显示显著获益。
要点
- FLT3-ITD插入位点可分为JMDsole、JMD/TKD1和TKD1sole三组,预后显著不同。
- TKD1sole组4年OS概率仅0.30,为独立不利预后因素。
- 米哚妥林仅对JMDsole组显示显著生存获益。
核心结论
- FLT3-ITD插入位点存在分子异质性,TKD1sole为不利预后因素,且未被米哚妥林克服。
研究设计与样本
- RATIFY试验中452例随机化AML患者的回顾性分析,采用二代测序鉴定FLT3-ITD插入位点。
主要发现
- 共鉴定908个ITD,643个位于JMD,265个位于TKD1。
- JMDsole、JMD/TKD1和TKD1sole三组4年OS概率分别为0.44、0.50和0.30(P=0.032)。
- NPM1突变与JMDsole相关(P=0.028)。
- 多因素Cox模型显示TKD1sole为不利因素,异基因HCT为有利因素。
- 米哚妥林仅对JMDsole组显示显著获益。
临床怎么用
- 对FLT3-ITD阳性AML患者可考虑插入位点分型以细化预后评估。
- TKD1sole患者预后较差,需探索更有效治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In acute myeloid leukemia (AML) internal tandem duplications of the FLT3 gene (FLT3-ITD) are associated with poor prognosis. Retrospectively, we investigated the prognostic and predictive impact of FLT3-ITD insertion site (IS) in 452 patients randomized within the RATIFY trial, which evaluated midostaurin additionally to intensive chemotherapy. Next-generation sequencing identified 908 ITDs, with 643 IS in the juxtamembrane domain (JMD) and 265 IS in the tyrosine kinase domain-1 (TKD1). According to IS, patients were categorized as JMDsole (n = 251, 55%), JMD and TKD1 (JMD/TKD1; n = 117, 26%), and TKD1sole (n = 84, 19%). While clinical variables did not differ among the 3 groups, NPM1 mutation was correlated with JMDsole (P = 0.028). Overall survival (OS) differed significantly, with estimated 4-year OS probabilities of 0.44, 0.50, and 0.30 for JMDsole, JMD/TKD1, and TKD1sole, respectively (P = 0.032). Multivariate (cause-specific) Cox models for OS and cumulative incidence of relapse using allogeneic hematopoietic cell transplantation (HCT) in first complete remission as a time-dependent variable identified TKD1sole as unfavorable and HCT as favorable factors. In addition, Midostaurin exerted a significant benefit only for JMDsole. Our results confirm the distinct molecular heterogeneity of FLT3-ITD and the negative prognostic impact of TKD1 IS in AML that was not overcome by midostaurin.
引用
- Rücker FG, Du L, Luck TJ, et al. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2021. PMID: 34316017. doi:10.1038/s41375-021-01323-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。